-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
RedHill Biopharma (NASDAQ:RDHL) Stock Crosses Below Two Hundred Day Moving Average of $1.46
RedHill Biopharma (NASDAQ:RDHL) Stock Crosses Below Two Hundred Day Moving Average of $1.46
RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.46 and traded as low as $0.82. RedHill Biopharma shares last traded at $0.87, with a volume of 954,952 shares traded.
RedHill Biopharma Price Performance
The company has a debt-to-equity ratio of 9.42, a current ratio of 0.98 and a quick ratio of 0.79. The company has a 50-day simple moving average of $0.94 and a two-hundred day simple moving average of $1.46. The stock has a market capitalization of $45.83 million, a price-to-earnings ratio of -0.46 and a beta of 1.86.
Get RedHill Biopharma alerts:RedHill Biopharma (NASDAQ:RDHL – Get Rating) last issued its earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative return on equity of 822.29% and a negative net margin of 110.31%. The firm had revenue of $18.24 million for the quarter. During the same period in the prior year, the business earned ($0.53) earnings per share. On average, equities research analysts predict that RedHill Biopharma Ltd. will post -0.95 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of RDHL. Cambridge Investment Research Advisors Inc. bought a new position in shares of RedHill Biopharma in the fourth quarter worth $71,000. HighTower Advisors LLC bought a new position in shares of RedHill Biopharma in the fourth quarter worth $32,000. GSA Capital Partners LLP grew its stake in shares of RedHill Biopharma by 108.4% in the fourth quarter. GSA Capital Partners LLP now owns 218,338 shares of the biotechnology company's stock worth $563,000 after purchasing an additional 113,584 shares in the last quarter. ARK Investment Management LLC bought a new position in shares of RedHill Biopharma in the first quarter worth $2,172,000. Finally, Gagnon Securities LLC grew its stake in shares of RedHill Biopharma by 15.4% in the first quarter. Gagnon Securities LLC now owns 367,346 shares of the biotechnology company's stock worth $926,000 after purchasing an additional 49,023 shares in the last quarter. Institutional investors own 7.74% of the company's stock.About RedHill Biopharma
(Get Rating)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Read More
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.46 and traded as low as $0.82. RedHill Biopharma shares last traded at $0.87, with a volume of 954,952 shares traded.
在周四的交易中，红山生物医药有限公司(纳斯达克代码：RDHL-GET评级)跌破了200日移动均线。该股的200日移动均线切入位为1.46美元，最低交易价格为0.82美元。红山生物医药的股票最新报0.87美元，总成交量为954,952股。
RedHill Biopharma Price Performance
红山生物医药的价格表现
The company has a debt-to-equity ratio of 9.42, a current ratio of 0.98 and a quick ratio of 0.79. The company has a 50-day simple moving average of $0.94 and a two-hundred day simple moving average of $1.46. The stock has a market capitalization of $45.83 million, a price-to-earnings ratio of -0.46 and a beta of 1.86.
该公司的债务权益比为9.42，流动比率为0.98，速动比率为0.79。该公司的50日简单移动均线切入位在0.94美元，200日简单移动均线切入位在1.46美元。该股市值为4,583万美元，市盈率为-0.46，贝塔系数为1.86。
RedHill Biopharma (NASDAQ:RDHL – Get Rating) last issued its earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative return on equity of 822.29% and a negative net margin of 110.31%. The firm had revenue of $18.24 million for the quarter. During the same period in the prior year, the business earned ($0.53) earnings per share. On average, equities research analysts predict that RedHill Biopharma Ltd. will post -0.95 earnings per share for the current year.
红山生物医药(纳斯达克代码：Rdhl-Get Rating)最近一次发布收益报告是在6月23日(星期四)。这家生物技术公司公布了本季度每股收益(0.30美元)，比普遍预期的(0.40美元)高出0.10美元。红山生物医药的净资产回报率为负822.29%，净利润率为负110.31%。该公司本季度的收入为1824万美元。去年同期，该业务实现每股收益(0.53美元)。股票研究分析师平均预测，红山生物科技有限公司本年度每股收益将为0.95美元。
Institutional Inflows and Outflows
机构资金流入和流出
About RedHill Biopharma
关于雷德希尔生物医药公司
(Get Rating)
(获取评级)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
红山生物制药有限公司是一家专业的生物制药公司，主要专注于胃肠道和传染病。该公司推广胃肠药物，包括用于治疗患有慢性非癌症疼痛的成人阿片类药物引起的便秘的Movantik；用于治疗成人幽门螺杆菌感染的Talicia；以及用于治疗成人旅行者腹泻的Aemcolo。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
- 免费获取StockNews.com关于RedHill Biophma(RDHL)的研究报告
- 耐克股票会被超卖，但仍被高估吗？
- 美国铝业是在第二季度业绩强劲和更多股票回购之后买入的吗？
- 皇家加勒比的宽带合作能否推动收入增长？
- 芯片设备制造商Entigis很有潜力，但它现在可以买下吗？
- DocuSign在报告收益时有重要的问题需要解决
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《红山生物报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对RedHill Biophma和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧